Assenagon Asset Management S.A. Has $2.27 Million Stake in Catalyst Pharmaceuticals, Inc. $CPRX

Assenagon Asset Management S.A. increased its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 8.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 104,375 shares of the biopharmaceutical company’s stock after purchasing an additional 7,746 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.09% of Catalyst Pharmaceuticals worth $2,265,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Park Square Financial Group LLC bought a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter worth approximately $29,000. Sound Income Strategies LLC bought a new stake in shares of Catalyst Pharmaceuticals in the 1st quarter worth approximately $64,000. GAMMA Investing LLC raised its holdings in shares of Catalyst Pharmaceuticals by 26.2% in the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 579 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 57.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,501 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 2,002 shares during the period. Finally, US Bancorp DE raised its holdings in shares of Catalyst Pharmaceuticals by 17.8% in the 1st quarter. US Bancorp DE now owns 7,328 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 1,105 shares during the period. Institutional investors own 79.22% of the company’s stock.

Insider Activity

In other news, CEO Richard J. Daly sold 22,970 shares of the company’s stock in a transaction dated Tuesday, August 26th. The shares were sold at an average price of $20.62, for a total transaction of $473,641.40. Following the completion of the transaction, the chief executive officer directly owned 226,794 shares of the company’s stock, valued at approximately $4,676,492.28. This represents a 9.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director David S. Tierney sold 26,000 shares of the company’s stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $20.20, for a total transaction of $525,200.00. Following the transaction, the director directly owned 379,620 shares of the company’s stock, valued at approximately $7,668,324. This trade represents a 6.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 243,970 shares of company stock valued at $4,927,241. 10.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, September 21st. Zacks Research lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Finally, Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, June 5th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $33.20.

Catalyst Pharmaceuticals Trading Down 2.9%

Shares of NASDAQ:CPRX opened at $19.13 on Friday. The company has a market cap of $2.34 billion, a price-to-earnings ratio of 11.59, a price-to-earnings-growth ratio of 0.79 and a beta of 0.85. The company has a 50-day moving average price of $20.43 and a 200-day moving average price of $22.25. Catalyst Pharmaceuticals, Inc. has a 12 month low of $19.05 and a 12 month high of $26.58.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.